BioVie Invited to Present Data on Bezisterim in Long COVID at the NIH's RECOVER-TLC Third Annual WorkshopGlobeNewsWire · 1 hr ago
BioVie reports positive Phase 2 Parkinson's data for bezisterimProactive Investors · 5 days ago
BioVie Presents Data on Bezisterim in Parkinson's Disease at the 2026 American Neurological Association Annual MeetingGlobeNewsWire · 6 days ago
BioVie says bezisterim eased fatigue and cognitive symptoms in Long COVID subgroupsProactive Investors · 6 days ago
BioVie to present Long COVID and Parkinson's trial results at American Neurological Association meetingProactive Investors · Oct 14, 2026
BioVie to Present New Bezisterim Findings in Parkinson's Disease and Long COVID at the 2026 American Neurological Association Annual MeetingGlobeNewsWire · Oct 14, 2026BioVie Inc. is a clinical-stage biotechnology firm primarily dedicated to the discovery, development, and commercialization of innovative drug treatments across the United States. The company's developmental portfolio includes BIV201, a therapeutic agent that has successfully completed its Phase IIa clinical trial for addressing ascites resulting from chronic liver cirrhosis. Additionally, BioVie is advancing NE3107, which is currently undergoing a Phase III clinical trial for the management of mild to moderate Alzheimer's disease, and is also in a Phase I clinical trial for the treatment of Parkinson's disease.
| Date | Est. | Actual | |
|---|---|---|---|
| Aug 12, 2026 | -$0.52 | -$0.70 | Miss |
| May 11, 2026 | -$0.73 | -$0.70 | Beat |
| Feb 10, 2026 | -$0.81 | -$0.77 | Beat |
| Nov 10, 2025 | -$0.79 | -$0.98 | Miss |
| Aug 15, 2025 | -$1.82 | -$1.82 | Beat |
| May 12, 2025 | -$3.20 | -$1.50 | Beat |